MarketsandMarkets Blog

The China healthcare electronic data interchange (EDI) market is in an early yet transformative stage, shifting from internal data exchange to standardized inter-organizational transactions. While many hospitals have adopted basic EDI for functions like accounting and medical charts, usage is often restricted by limited IT infrastructure and a business culture that heavily emphasizes personal relationships....

The China telehealth and telemedicine market is a rapidly expanding and transformative sector of the healthcare industry, driven by the country’s vast population, aging demographics, and a significant urban-rural healthcare resource gap. The landscape is characterized by robust government support through initiatives like the Healthy China 2030 plan and the rapid rollout of 5G infrastructure,...

The China clinical decision support systems market is a rapidly evolving sector of the healthcare IT industry, fueled by government-backed digitalization initiatives and the widespread adoption of electronic medical records in tertiary hospitals. The landscape is characterized by a significant move toward “medical digitalization,” with the market projected to grow at a robust CAGR of 15%...

The China biopharmaceutical CDMO market is a rapidly maturing ecosystem that has evolved from a low-cost manufacturing hub into a global leader in high-tech innovation and scalable drug development. Driven by robust government backing, such as the Healthy China 2030 plan, and a massive chemistry workforce, the landscape is characterized by a strategic shift toward complex modalities including monoclonal...

The China blood glucose monitoring devices market is a rapidly expanding sector of the healthcare industry, driven by a massive and aging diabetic population and a significant shift toward digital health integration. The landscape is currently defined by a transition from traditional self-monitoring blood glucose meters toward more advanced, real-time continuous glucose monitoring (CGM) systems, which...

The China central lab services market is a rapidly expanding sector driven by a burgeoning clinical research landscape, increasing R&D investments, and a high prevalence of chronic diseases. The market is characterized by a significant shift toward the integration of artificial intelligence and automation to enhance diagnostic accuracy and accelerate drug development timelines. Key segments such...

The China PCR technologies market is a rapidly growing sector characterized by a strong shift toward domestic manufacturing and the widespread adoption of advanced molecular diagnostics. Driven by government initiatives such as procurement protection policies for local suppliers and significant investments in healthcare infrastructure, the landscape is evolving from a reliance on imported brands to...

The China medical billing market is a dynamic and rapidly expanding sector driven by large-scale hospital digitization, stringent government policies, and the integration of advanced technologies like artificial intelligence and big data analytics. The landscape is characterized by a significant shift toward smart hospital systems to improve administrative efficiency, forcing providers to adopt digital...

The China point-of-care molecular diagnostics market is a rapidly evolving and burgeoning sector driven by the national implementation of graded diagnosis and treatment and an increasing burden of infectious and chronic diseases among an aging population. While the landscape has historically been dominated by global giants like Roche, Abbott, and Danaher, local players are increasingly emerging through...

The China human microbiome market is an rapidly expanding sector within the country’s biotechnology landscape, characterized by a transition from basic research to the commercialization of sophisticated, clinically focused solutions. Driven by a large population base and a high prevalence of lifestyle and gastrointestinal disorders, the market is benefiting from significant government support through...